Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
作者信息
Gran Charlotte, Luong Vincent, Bruchfeld Johanna B, Liwing Johan, Afram Gabriel, Lund Johan, Usmani Saad, Alici Evren, Nahi Hareth
机构信息
Center for Hematology and Regenerative Medicine (HERM), Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, Sweden.
出版信息
Am J Hematol. 2021 Mar 1;96(3):E63-E65. doi: 10.1002/ajh.26062. Epub 2020 Dec 19.
Abstract
摘要
相似文献
1
Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.冒烟型多发性骨髓瘤的动态随访可识别出进展风险高的患者亚组。
Am J Hematol. 2021 Mar 1;96(3):E63-E65. doi: 10.1002/ajh.26062. Epub 2020 Dec 19.
2
Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.基线血清 B 细胞成熟抗原水平可预测冒烟型多发性骨髓瘤患者的疾病进展时间。
Eur J Haematol. 2021 Sep;107(3):318-323. doi: 10.1111/ejh.13666. Epub 2021 Jun 14.
3
New strategies for MGUS and smoldering multiple myeloma.意义未明的单克隆丙种球蛋白病和冒烟型多发性骨髓瘤的新策略。
Clin Adv Hematol Oncol. 2004 Aug;2(8):507, 509.
4
Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.M蛋白和血红蛋白的动态变化作为冒烟型多发性骨髓瘤进展的预测指标
Blood Cancer J. 2018 Nov 8;8(11):107. doi: 10.1038/s41408-018-0144-x.
5
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.冒烟型多发性骨髓瘤的风险分层：游离轻链和基于群组的轨迹建模的预测价值。
Blood Adv. 2018 Jun 26;2(12):1470-1479. doi: 10.1182/bloodadvances.2018016998.
6
Reference change values of M-protein, free light chain and immunoglobulins in monoclonal gammopathy.单克隆丙种球蛋白病中 M 蛋白、游离轻链和免疫球蛋白的参考变化值。
Clin Biochem. 2019 Dec;74:42-46. doi: 10.1016/j.clinbiochem.2019.09.004. Epub 2019 Sep 14.
7
Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used.多发性骨髓瘤中游离轻链的诊断阈值取决于所使用的检测方法。
Leukemia. 2018 Aug;32(8):1815-1818. doi: 10.1038/s41375-018-0041-0. Epub 2018 Apr 20.
8
The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.血清κ/λ比值对意义未明的单克隆丙种球蛋白病和多发性骨髓瘤鉴别的预测能力。
Clin Chem Lab Med. 2005;43(1):32-7. doi: 10.1515/CCLM.2005.004.
9
The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma.骨髓免疫组化κ/λ 比值用于多发性骨髓瘤诊断的截断值。
Hematology. 2020 Dec;25(1):292-298. doi: 10.1080/16078454.2020.1802929.
10
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.浆细胞增生指数是冒烟型多发性骨髓瘤进展的独立预测因子。
Blood Adv. 2018 Nov 27;2(22):3149-3154. doi: 10.1182/bloodadvances.2018024794.
引用本文的文献
1
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).利用动态生物标志物对冒烟型多发性骨髓瘤进行强化风险分层：一项纳入2270名参与者的多国多中心研究（PANGEA 2.0）。
Res Sq. 2025 Jun 3:rs.3.rs-6696313. doi: 10.21203/rs.3.rs-6696313/v1.
2
The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma.单克隆蛋白的演变模式改进了国际骨髓瘤工作组（IMWG）针对冒烟型多发性骨髓瘤患者的2/20/20分类。
Hemasphere. 2024 May 6;8(5):e76. doi: 10.1002/hem3.76. eCollection 2024 May.
3
The consultant's guide to smoldering multiple myeloma.冒烟型多发性骨髓瘤的顾问指南。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):551-559. doi: 10.1182/hematology.2022000355.
4
Risk Stratification and Treatment in Smoldering Multiple Myeloma.冒烟型多发性骨髓瘤的风险分层与治疗。
Cells. 2021 Dec 31;11(1):130. doi: 10.3390/cells11010130.
5
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.冒烟型多发性骨髓瘤：不断演变的诊断标准与治疗策略。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):673-681. doi: 10.1182/hematology.2021000304.
6
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis.评估冒烟型多发性骨髓瘤风险分层评分在诊断后连续应用的预后效用。
Blood Cancer J. 2021 Nov 26;11(11):186. doi: 10.1038/s41408-021-00569-2.
7
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.2021 年欧洲骨髓瘤网络关于冒烟型多发性骨髓瘤的回顾和共识声明：如何区分（和管理）杰基尔博士和海德先生。
Haematologica. 2021 Nov 1;106(11):2799-2812. doi: 10.3324/haematol.2021.278519.
本文引用的文献
1
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.免疫标志物变化与意义未明的单克隆丙种球蛋白病进展为多发性骨髓瘤的相关性
JAMA Oncol. 2019 Sep 1;5(9):1293-1301. doi: 10.1001/jamaoncol.2019.1568.
2
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.冒烟型多发性骨髓瘤的风险分层：游离轻链和基于群组的轨迹建模的预测价值。
Blood Adv. 2018 Jun 26;2(12):1470-1479. doi: 10.1182/bloodadvances.2018016998.
3
Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.冒烟型多发性骨髓瘤患者 M 蛋白模式的演变：对早期进展的影响。
Leukemia. 2018 Jun;32(6):1427-1434. doi: 10.1038/s41375-018-0013-4. Epub 2018 Feb 2.
4
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.冒烟型多发性骨髓瘤中疾病生物标志物的动态变化与早期进展风险
Blood Cancer J. 2016 Jul 29;6(7):e454. doi: 10.1038/bcj.2016.65.
5
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.来那度胺联合地塞米松与观察治疗高危冒烟型多发性骨髓瘤患者（QuiRedex）：一项随机、对照、3 期临床试验的长期随访。
Lancet Oncol. 2016 Aug;17(8):1127-1136. doi: 10.1016/S1470-2045(16)30124-3. Epub 2016 Jul 9.
6
A multicentre study comparing two methods for serum free light chain analysis.多中心研究比较两种血清游离轻链分析方法。
Ann Clin Biochem. 2013 May;50(Pt 3):255-61. doi: 10.1177/0004563212473447.
7
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.冒烟型多发性骨髓瘤进展风险的建模：一项前瞻性临床研究的结果。
Leuk Lymphoma. 2013 Oct;54(10):2215-8. doi: 10.3109/10428194.2013.764419. Epub 2013 Jul 29.
8
Smoldering multiple myeloma: natural history and recognition of an evolving type.冒烟型多发性骨髓瘤：自然病程及一种演变类型的识别
Br J Haematol. 2003 Nov;123(4):631-6. doi: 10.1046/j.1365-2141.2003.04654.x.
Zotero 插件